160 related articles for article (PubMed ID: 28985276)
1. Mortality and Macrovascular Risk in Elderly With Hypertension and Diabetes: Effect of Intensive Drug Therapy.
Yashkin AP; Kravchenko J; Yashin AI; Sloan F
Am J Hypertens; 2018 Jan; 31(2):220-227. PubMed ID: 28985276
[TBL] [Abstract][Full Text] [Related]
2. Severity of Diabetic Retinopathy and the Risk of Future Cerebrovascular Disease, Cardiovascular Disease, and All-Cause Mortality.
Modjtahedi BS; Wu J; Luong TQ; Gandhi NK; Fong DS; Chen W
Ophthalmology; 2021 Aug; 128(8):1169-1179. PubMed ID: 33359888
[TBL] [Abstract][Full Text] [Related]
3. Adherence to Guidelines for Screening and Medication Use: Mortality and Onset of Major Macrovascular Complications in Elderly Persons With Diabetes Mellitus.
Yashkin AP; Sloan F
J Aging Health; 2018 Apr; 30(4):503-520. PubMed ID: 28553792
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
Shin H; Schneeweiss S; Glynn RJ; Patorno E
Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
7. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Chen YJ; Li LJ; Tang WL; Song JY; Qiu R; Li Q; Xue H; Wright JM
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008170. PubMed ID: 30480768
[TBL] [Abstract][Full Text] [Related]
8. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
Spence JD; Viscoli CM; Inzucchi SE; Dearborn-Tomazos J; Ford GA; Gorman M; Furie KL; Lovejoy AM; Young LH; Kernan WN;
JAMA Neurol; 2019 May; 76(5):526-535. PubMed ID: 30734043
[TBL] [Abstract][Full Text] [Related]
11. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
12. Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up.
Jansson SP; Svärdsudd K; Andersson DK
Diabet Med; 2014 Sep; 31(9):1055-63. PubMed ID: 24894815
[TBL] [Abstract][Full Text] [Related]
13. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
Ou HT; Chang KC; Li CY; Wu JS
Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive Medication Adherence and Risk of Cardiovascular Disease Among Older Adults: A Population-Based Cohort Study.
Yang Q; Chang A; Ritchey MD; Loustalot F
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28647688
[TBL] [Abstract][Full Text] [Related]
16. Urinary sodium and potassium excretion and risk of cardiovascular events.
O'Donnell MJ; Yusuf S; Mente A; Gao P; Mann JF; Teo K; McQueen M; Sleight P; Sharma AM; Dans A; Probstfield J; Schmieder RE
JAMA; 2011 Nov; 306(20):2229-38. PubMed ID: 22110105
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
18. Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65 years or older: a nationwide population-based cohort study.
Christiansen CF; Thomsen RW; Schmidt M; Pedersen L; Sørensen HT
Intensive Care Med; 2019 Jul; 45(7):957-967. PubMed ID: 31187170
[TBL] [Abstract][Full Text] [Related]
19. Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: A nationwide study.
Lee YB; Han K; Kim B; Choi MS; Park J; Kim M; Jin SM; Hur KY; Kim G; Kim JH
J Diabetes Investig; 2021 Oct; 12(10):1855-1863. PubMed ID: 33662172
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC
Ann Intern Med; 2021 Nov; 174(11):1528-1541. PubMed ID: 34570599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
